Skip to content

Study · Non-randomized trial · n = 24 · 2012

8 results

Kisspeptin-10 stimulation of gonadotrophin secretion in women is modulated by sex steroid feedback.

George JT, Anderson RA, Millar RP

Human reproduction (Oxford, England)5 Sept 2012Cited by 42 (Europe PMC)

PMID22956346 (opens in a new tab)DOI10.1093/humrep/des326 (opens in a new tab)PepBankPUB-22956346
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In post-menopausal women, the LH response to kisspeptin‑10 was significantly larger than in the other groups.

    In plain wordsIn post-menopausal women, the LH response to kisspeptin‑10 was larger than in the other groups of women.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseLH response in post-menopausal women versus other groups
    Study

    n = 24

    Comparator
    Other groups
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.3 µg/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Both LH and FSH responses in post-menopausal women were significantly larger than the other groups (one-way ANOVA analysis of ΔAUC; LH (P = 0.012) and FSH (P = 0.001)].
    2 context sentences
    Summary · context
    The gonadotrophin response to intravenous kisspeptin-10 (0.3 µg/kg) in women in the early follicular phase was compared with that in the presence of low endogenous sex steroids/high gonadotrophin secretion (post-menopausal women) and in women taking sex-steroid contraceptives (combined pill, n = 4;…
    Summary · context
    Area under the curve (AUC) of gonadotrophin secretion sampled at 15 min intervals over 60 min before and after kisspeptin-10 was analysed.
  2. 02HumanNon-randomized trialEfficacy outcome

    In post-menopausal women, the FSH response to kisspeptin‑10 was significantly larger than in the other groups.

    In plain wordsIn post-menopausal women, the FSH response to kisspeptin‑10 was larger than in the other groups of women.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseFSH response in post-menopausal women versus other groups
    Study

    n = 24

    Comparator
    Other groups
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.3 µg/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Both LH and FSH responses in post-menopausal women were significantly larger than the other groups (one-way ANOVA analysis of ΔAUC; LH (P = 0.012) and FSH (P = 0.001)].
    2 context sentences
    Summary · context
    The gonadotrophin response to intravenous kisspeptin-10 (0.3 µg/kg) in women in the early follicular phase was compared with that in the presence of low endogenous sex steroids/high gonadotrophin secretion (post-menopausal women) and in women taking sex-steroid contraceptives (combined pill, n = 4;…
    Summary · context
    Area under the curve (AUC) of gonadotrophin secretion sampled at 15 min intervals over 60 min before and after kisspeptin-10 was analysed.
  3. 03HumanNon-randomized trialEfficacy outcome

    In women in the early follicular phase, intravenous kisspeptin‑10 increased LH secretion (change in AUC 2.3 IU/l h).

    In plain wordsIn women in the early follicular phase, kisspeptin‑10 raised LH release compared with before the dose.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseLH secretion in early follicular phase women
    Study

    n = 10

    Comparator
    Pre-dose baseline
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.3 µg/kg · intravenousAs given in this study (human).

    Measurements

    LH ΔAUC
    2.3 IU/l h
    early follicular

    Source sentences

    Summary
    Kisspeptin-10 stimulated LH secretion in follicular (ΔAUC 2.3 ± 0.8 IU/l h, P = 0.009), post-menopausal (5.3 ± 0.9 IU/l h P 0.002) and progestogen (2.6 ± 0.8 IU/l h P 0.05) groups but not in women taking combined pill (0.9 ± 0.4 IU/l h P 0.13).
    2 context sentences
    Summary · context
    The gonadotrophin response to intravenous kisspeptin-10 (0.3 µg/kg) in women in the early follicular phase was compared with that in the presence of low endogenous sex steroids/high gonadotrophin secretion (post-menopausal women) and in women taking sex-steroid contraceptives (combined pill, n = 4;…
    Summary · context
    Area under the curve (AUC) of gonadotrophin secretion sampled at 15 min intervals over 60 min before and after kisspeptin-10 was analysed.
  4. 04HumanNon-randomized trialEfficacy outcome

    In post-menopausal women, intravenous kisspeptin‑10 increased LH secretion (change in AUC 5.3 IU/l h).

    In plain wordsIn post-menopausal women, kisspeptin‑10 raised LH release compared with before the dose.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseLH secretion in post-menopausal women
    Study

    n = 6

    Comparator
    Pre-dose baseline
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.3 µg/kg · intravenousAs given in this study (human).

    Measurements

    LH ΔAUC
    5.3 IU/l h
    post-menopausal

    Source sentences

    Summary
    Kisspeptin-10 stimulated LH secretion in follicular (ΔAUC 2.3 ± 0.8 IU/l h, P = 0.009), post-menopausal (5.3 ± 0.9 IU/l h P 0.002) and progestogen (2.6 ± 0.8 IU/l h P 0.05) groups but not in women taking combined pill (0.9 ± 0.4 IU/l h P 0.13).
    2 context sentences
    Summary · context
    The gonadotrophin response to intravenous kisspeptin-10 (0.3 µg/kg) in women in the early follicular phase was compared with that in the presence of low endogenous sex steroids/high gonadotrophin secretion (post-menopausal women) and in women taking sex-steroid contraceptives (combined pill, n = 4;…
    Summary · context
    Area under the curve (AUC) of gonadotrophin secretion sampled at 15 min intervals over 60 min before and after kisspeptin-10 was analysed.
  5. 05HumanNon-randomized trialEfficacy outcome

    In post-menopausal women, intravenous kisspeptin‑10 significantly increased FSH secretion (change in AUC 2.6 IU/l h).

    In plain wordsIn post-menopausal women, kisspeptin‑10 raised FSH release compared with before the dose.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseFSH secretion in post-menopausal women
    Study

    n = 6

    Comparator
    Pre-dose baseline
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.3 µg/kg · intravenousAs given in this study (human).

    Measurements

    FSH ΔAUC
    2.6 IU/l h
    post-menopausal

    Source sentences

    Summary
    FSH secretion was significantly increased only in post-menopausal women (ΔAUC 2.6 ± 0.8 IU/l h P = 0.03) with changes of <0.5 IU/l h observed in the other three groups.
    2 context sentences
    Summary · context
    The gonadotrophin response to intravenous kisspeptin-10 (0.3 µg/kg) in women in the early follicular phase was compared with that in the presence of low endogenous sex steroids/high gonadotrophin secretion (post-menopausal women) and in women taking sex-steroid contraceptives (combined pill, n = 4;…
    Summary · context
    Area under the curve (AUC) of gonadotrophin secretion sampled at 15 min intervals over 60 min before and after kisspeptin-10 was analysed.
  6. 06HumanNon-randomized trialEfficacy outcome

    In women taking progestogen implants, intravenous kisspeptin‑10 increased LH secretion (change in AUC 2.6 IU/l h).

    In plain wordsIn women using progestogen implants, kisspeptin‑10 raised LH release compared with before the dose.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseLH secretion in women taking progestogen implants
    Study

    n = 4

    Comparator
    Pre-dose baseline
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.3 µg/kg · intravenousAs given in this study (human).

    Measurements

    LH ΔAUC
    2.6 IU/l h
    progestogen implant

    Source sentences

    Summary
    Kisspeptin-10 stimulated LH secretion in follicular (ΔAUC 2.3 ± 0.8 IU/l h, P = 0.009), post-menopausal (5.3 ± 0.9 IU/l h P 0.002) and progestogen (2.6 ± 0.8 IU/l h P 0.05) groups but not in women taking combined pill (0.9 ± 0.4 IU/l h P 0.13).
    2 context sentences
    Summary · context
    The gonadotrophin response to intravenous kisspeptin-10 (0.3 µg/kg) in women in the early follicular phase was compared with that in the presence of low endogenous sex steroids/high gonadotrophin secretion (post-menopausal women) and in women taking sex-steroid contraceptives (combined pill, n = 4;…
    Summary · context
    Area under the curve (AUC) of gonadotrophin secretion sampled at 15 min intervals over 60 min before and after kisspeptin-10 was analysed.
  7. 07HumanNon-randomized trialEfficacy outcome

    In women taking the combined pill, intravenous kisspeptin‑10 did not significantly change LH secretion (change in AUC 0.9 IU/l h).

    In plain wordsIn women taking the combined pill, kisspeptin‑10 did not clearly change LH release compared with before the dose.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeLH secretion in women taking the combined pill
    Study

    n = 4

    Comparator
    Pre-dose baseline
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.3 µg/kg · intravenousAs given in this study (human).

    Measurements

    LH ΔAUC
    0.9 IU/l h
    combined pill

    Source sentences

    Summary
    Kisspeptin-10 stimulated LH secretion in follicular (ΔAUC 2.3 ± 0.8 IU/l h, P = 0.009), post-menopausal (5.3 ± 0.9 IU/l h P 0.002) and progestogen (2.6 ± 0.8 IU/l h P 0.05) groups but not in women taking combined pill (0.9 ± 0.4 IU/l h P 0.13).
    2 context sentences
    Summary · context
    The gonadotrophin response to intravenous kisspeptin-10 (0.3 µg/kg) in women in the early follicular phase was compared with that in the presence of low endogenous sex steroids/high gonadotrophin secretion (post-menopausal women) and in women taking sex-steroid contraceptives (combined pill, n = 4;…
    Summary · context
    Area under the curve (AUC) of gonadotrophin secretion sampled at 15 min intervals over 60 min before and after kisspeptin-10 was analysed.
  8. 08HumanNon-randomized trialEfficacy outcome

    In the other three groups (follicular, combined pill, progestogen implant), kisspeptin‑10 changed FSH secretion by less than 0.5 IU/l h, with no significant increase.

    In plain wordsIn women who were not post-menopausal, kisspeptin‑10 caused no significant rise in FSH release.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeFSH secretion in follicular, pill and implant groups
    Study

    n: not reported in source

    Comparator
    Pre-dose baseline
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.3 µg/kg · intravenousAs given in this study (human).

    Measurements

    FSH ΔAUC
    < 0.5 IU/l h
    other three groups

    Source sentences

    Summary
    FSH secretion was significantly increased only in post-menopausal women (ΔAUC 2.6 ± 0.8 IU/l h P = 0.03) with changes of <0.5 IU/l h observed in the other three groups.
    2 context sentences
    Summary · context
    The gonadotrophin response to intravenous kisspeptin-10 (0.3 µg/kg) in women in the early follicular phase was compared with that in the presence of low endogenous sex steroids/high gonadotrophin secretion (post-menopausal women) and in women taking sex-steroid contraceptives (combined pill, n = 4;…
    Summary · context
    Area under the curve (AUC) of gonadotrophin secretion sampled at 15 min intervals over 60 min before and after kisspeptin-10 was analysed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.